UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline

 
• By Sten Stovall
Emerging Company Profile: Monument Therapeutics
Spinout has access to vast library of validated CNS biomarkers created by its parent • Source: Alamy

More from Neurological

More from Therapy Areas